Nicox Announces Positive Phase 3 Results for NCX 470 at the American Glaucoma Society Congress
On Tuesday, Nicox unveiled favorable Phase 3 clinical data for NCX 470, its leading development program. These results were presented at the 2026 annual congress of the American Glaucoma Society, a major scientific event in the ophthalmology sector.
Significant Reduction in Intraocular Pressure Demonstrated
Phase 3 studies on NCX 470, a novel fast-acting molecule, demonstrated a reduction in intraocular pressure of up to ten millimeters of mercury compared to baseline. These results meet the efficacy requirements for market approval applications in the United States and China. Three presentations were highlighted during the congress held from February 19 to 22, 2026: two oral podium presentations and one poster. The Phase 3 Denali clinical study achieved its primary endpoint by demonstrating the non-inferiority of 0.1% NCX 470 compared to 0.005% latanoprost at all measurement points. NCX 470 showed a rapid, powerful, and consistent reduction in intraocular pressure, statistically superior to latanoprost at three of the six measurement points. The safety and tolerance profile was favorable, with a low treatment discontinuation rate.
Exploring the Dynamics of Aqueous Humor with NCX 470
A second oral presentation focused on the aqueous humor dynamics of NCX 470. This Phase 3b study was conducted as a double-blind, placebo-controlled trial involving healthy adults without glaucoma. Participants received either artificial tears or 0.1% NCX 470, administered once daily. The results indicate that NCX 470 significantly reduced intraocular pressure through a dual mechanism of action, enhancing both trabecular outflow and uveoscleral flow. A poster presenting the results in the American subgroup of the Denali study confirmed a robust reduction in intraocular pressure in patients with glaucoma or ocular hypertension, with favorable safety and tolerance profiles.
Global Licensing and Partnerships
NCX 470 is licensed to Ocumension Therapeutics for the Chinese, Korean, and Southeast Asian markets, and to Kowa for the rest of the world. Nicox is also advancing a preclinical research program, NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, in partnership with Glaukos. The company's portfolio also includes VYZULTA, licensed globally to Bausch + Lomb for glaucoma and marketed in the United States and fifteen other territories, as well as ZERVIATE for allergic conjunctivitis. Nicox is listed on Euronext Growth Paris under the ticker symbol ALCOX.
